<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02776670</url>
  </required_header>
  <id_info>
    <org_study_id>EXB107-P001</org_study_id>
    <nct_id>NCT02776670</nct_id>
  </id_info>
  <brief_title>Clinical Outcomes Following Treatment With SYSTANE® BALANCE</brief_title>
  <official_title>Clinical Evaluation Following Use of SYSTANE® BALANCE in Subjects With Lipid-Deficient Dry Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical effectiveness of SYSTANE® BALANCE
      compared to REFRESH OPTIVE® Advanced in subjects with lipid-deficient dry eye.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 29, 2016</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Tear film break-up time (TFBUT) at Day 35</measure>
    <time_frame>Day 35</time_frame>
    <description>Assessment for noninferiority</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in TFBUT at Day 35</measure>
    <time_frame>Day 35</time_frame>
    <description>Assessment for superiority</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid layer thickness (LLT) Area Under the Curve (AUC120) at Day 35</measure>
    <time_frame>Day 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Global Ocular Discomfort Visual Analog Scale (VAS) score at Day 35</measure>
    <time_frame>Day 35</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">308</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>SYSTANE BALANCE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preservative-free 0.9% saline solution, 1 drop in each eye 4 times a day for 7-14 days as run-in, followed by propylene glycol, 0.6% eye drops, 1 drop in each eye 4 times per day for 35 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>REFRESH OPTIVE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Preservative-free 0.9% saline solution, 1 drop in each eye 4 times a day for 7-14 days as run-in, followed by lubricant eye drops, 1 drop in each eye 4 times per day for 35 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Propylene glycol, 0.6% eye drops</intervention_name>
    <arm_group_label>SYSTANE BALANCE</arm_group_label>
    <other_name>SYSTANE® BALANCE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lubricant eye drops</intervention_name>
    <arm_group_label>REFRESH OPTIVE</arm_group_label>
    <other_name>REFRESH OPTIVE® Advanced</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Preservative-free 0.9% saline solution</intervention_name>
    <arm_group_label>SYSTANE BALANCE</arm_group_label>
    <arm_group_label>REFRESH OPTIVE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to attend all study visits;

          -  Must sign an informed consent form;

          -  Best-corrected visual acuity (BCVA) of 55 letters or better in each eye as assessed
             using an early treatment diabetic retinopathy study (ETDRS) chart;

          -  Willing to take study products as directed for entire study;

          -  Other protocol-specified inclusion criteria may apply.

        Exclusion Criteria:

          -  Women of childbearing potential who are pregnant, plan to become pregnant during the
             study, breast feeding, or not using adequate birth control methods;

          -  Contact lens use within 30 days prior to Screening Visit, or unwilling to avoid
             contact lens use during the course of the study;

          -  Use of medication excluded by the protocol;

          -  Diseases, illnesses, infections, or ocular abnormalities excluded by the protocol;

          -  Ocular surgeries or procedures excluded by the protocol;

          -  Other protocol-specified exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Project Manager, PLS</last_name>
    <role>Study Director</role>
    <affiliation>Alcon, a Novartis Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Contact Alcon Call Center for Trial Locations</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2016</study_first_submitted>
  <study_first_submitted_qc>May 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2016</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Lubricant Eye Drops</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

